When considering plasmatic ADAM10, the protein achieved 72% sensitivity and 100% specificity, at the cutoff > 1.8 ng/mL, to correctly differentiate among healthy controls versus MCI and AD patients [12]. This evidence concerns the gene ADAM10 and Alzheimer disease.